The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Preventing progression to ATLL in HTLV-1 carriers
Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, discusses the importance of developing methods to prevent human T-cell leukemia virus type I (HTLV-1) carriers from progressing to adult T-cell leukemia/lymphoma (ATLL). Dr Phillips highlights novel methods using HTLV-1 proviral load monitoring to identify patients at risk of progression to ATL. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
